Reproductive Health Devices are used to manage conditions related to the reproductive system, its functions and processes. The Reproductive Health Devices include Endometrial Ablation Devices, Female Sterilization Devices, Reversible Contraceptive Devices, Assisted Reproductive Technology (ART) Devices, and Postpartum Hemorrhage Control Devices. Female sterilization is a permanent intervention where the fallopian tubes are blocked using surgical and non-surgical techniques. GlobalData uses proprietary data and analytics to provide a comprehensive report on the female sterilization devices devices market, including market shares of different players within China. Buy the latest report here.
Smarter leaders trust GlobalData
In 2023, GlobalData’s Market Model methodology determined that the leading player in the female sterilization devices market in China was Gyrus ACMI and Utah Medical Products.
The fallopian tubes are blocked to prevent the sperm from fertilizing the egg, thereby preventing the woman from getting pregnant. This includes Female Sterilization Devices used in laparoscopic sterilization.
The value of the female sterilization devices devices market within China was expected to be over $3m in 2023.
For the latest complete market share analysis of female sterilization devices device market in China, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
